Novo Nordisk A/S (NVO)
| Market Cap | 460.13B |
| Revenue (ttm) | 30.42B |
| Net Income (ttm) | 10.68B |
| Shares Out | 4.45B |
| EPS (ttm) | 2.47 |
| PE Ratio | 41.71 |
| Forward PE | 31.55 |
| Dividend | $0.74 (0.71%) |
| Ex-Dividend Date | Aug 18, 2023 |
| Volume | 2,055,360 |
| Open | 103.55 |
| Previous Close | 103.47 |
| Day's Range | 102.73 - 103.68 |
| 52-Week Range | 65.05 - 105.69 |
| Beta | 0.19 |
| Analysts | Strong Buy |
| Price Target | 90.13 (-12.88%) |
| Earnings Date | Jan 31, 2024 |
About NVO
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and h... [Read more]
Financial Performance
In 2022, Novo Nordisk's revenue was 176.95 billion, an increase of 25.68% compared to the previous year's 140.80 billion. Earnings were 55.53 billion, an increase of 16.27%.
Financial numbers in DKK Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for NVO stock is "Strong Buy." The 12-month stock price forecast is $90.13, which is a decrease of -12.88% from the latest price.
News
Obesity drug enthusiasm can continue in 2024: Mizuho's Jared Holz
Mizuho's Jared Holz joins 'Fast Money' to talk enthusiasm surrounding obesity drugs and if that can endure into 2024.
Healthcare Stocks Had a Terrible 2023. Things Are Looking Up.
Things could hardly have gone worse for healthcare investors this year.
Novo Nordisk, FDA warn of fake Ozempic
The U.S. Food and Drug Administration has seized thousands of units of fake Ozempic, the agency said Thursday, warning that some counterfeit units of the Novo Nordisk NVO, -0.15% diabetes drug may sti...
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 22 December 2023 – On 6 November 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Coun...
US FDA warns about counterfeit versions of Novo's diabetes drug Ozempic
The U.S. Food and Drug Administration on Thursday warned consumers not to use counterfeit versions of Novo Nordisk's diabetes drug Ozempic that have been found in the country's drug supply chain.
Five obesity-drug trends to watch in 2024: Who can compete with Eli Lilly and Novo Nordisk?
The obesity drugs that powered huge investor gains in 2023 are poised to inspire more corporate dealmaking, scientific breakthroughs and better patient access in the year ahead, analysts say.
Weight-loss drugs poised for big 2024 as demand surges
CNBC's Karen Gilchrist reviews the growth of the weight-loss drug industry and its outlook for 2024.
Ozempic overshoot will plump up bargain-hunters
Weight-loss drug excitement went overboard in 2023. Novo Nordisk's Wegovy – which is known as Ozempic when used to treat diabetes – and Eli Lilly's Zepbound are the first effective treatments for obes...
Fake Wegovy: Pharma Giant Novo Nordisk Reportedly Steps Up Efforts Tackling Illegal Weight Loss Drugs Sold Online
One of India's leading online marketplaces is working with pharma giant Novo Nordisk to tackle illegal sales of popular weight loss drug Wegovy, Reuters reported Monday, as its soaring popularity and ...
Novo owner commits $265 mln of Wegovy windfall to respiratory diseases
The Novo Nordisk Foundation, which controls drug maker Novo Nordisk, said on Monday it would commit up to 1.8 billion Danish crowns ($265 million) to setting up an initiative aimed at improving vaccin...
Exclusive: IndiaMART is working with Novo Nordisk to halt illegal Wegovy sales -source
Indian online marketplace IndiaMART has been removing unauthorized listings of Novo Nordisk's blockbuster weight-loss drug Wegovy after holding talks with the Danish drugmaker in early October, a sour...
Ozempic and Wegovy lead Novo Nordisk to Yahoo Finance's Company of the Year
Novo Nordisk (NVO) and more specifically its weight-loss drugs Ozempic and Wagovy have been the topic of many conversations across Wall Street. The company's financial performance, impact and buzz has...
Novo Nordisk: Everything investors need to know
Yahoo Finance selected pharmaceutical firm Novo Nordisk (NVO) as it's 2023 Company of the Year. Developer of obesity medications Wegovy and Ozempic, Novo Nordisk stock has gained over 40% year-to-date...
Novo Nordisk: Yahoo Finance's Company of the Year, 2023
Novo Nordisk (NVO) and more specifically its blockbuster weight-loss drugs Ozempic and Wagovy have been the topic of many conversations across Wall Street and well beyond this year, due to the company...
Why Novo Nordisk's corporate structure stands out
Yahoo Finance selected Novo Nordisk (NVO) as its Company of the Year for 2023, and there are plenty of reasons why. One interesting reason some investors may not know about, however, is its unique cor...
Novo, Lilly rivals explore booming weight-loss drug market entry
Novo Nordisk and Eli Lilly have pulled ahead in the race for a slice of the weight-loss drugs market, expected to be worth $100 billion by the end of the decade, and rivals are looking to catch up thr...
Goldman Sachs money manager digs into three themes for long-term growth
Most exchange-traded funds are passively managed — they are designed to mirror the performance of stock indexes and typically have low management fees. They can work out very well for investors, which...
No more exercising? President RFK Jr.? Here's one bank's outrageous predictions for 2024
Denmark's Saxo Bank makes a tradition of making “outrageous predictions,” which every once in a while comes true. The bank counts as a win its 2022 prediction that the plan to end fossil fuels will ge...
Ozempic vs. Mounjaro:: Battle of the bulge
The year 2023 was a breakout year for glucagon-like peptide (GLP-1) weight-loss drugs in the medical sector, led by the popularity of Ozempic. Celebrity usage and social media exposure have caused Nov...
Roche Strikes $3.1 Billion Deal for Obesity Drugmaker. It Hopes to Compete with Eli Lilly, Novo Nordisk.
Roche has agreed to buy obesity-drug developer Carmot Therapeutics for up to $3.1 billion. The Swiss company is hoping to join Eli Lilly and Novo Nordisk at the forefront of the weight-loss drug marke...
Roche strikes $3.1 billion deal to buy obesity-drug maker Carmot Therapeutics billion in race to rival Novo Nordisk's Ozempic
Roche has agreed to buy obesity-drug developer Carmot Therapeutics for up to $3.1 billion, as the world's top drugmakers rush to capitalize on the booming market for weight-loss drugs that has seen No...
There's still a long runway for obesity drugs, says Cantor Fitzgerald's Louise Chen
Louise Chen, Cantor Fitzgerald analyst, joins 'Squawk on the Street' to discuss what's already priced into the big GLP-1 manufacturing stocks, Chen's thoughts on these companies over the long-term, an...
Eli Lilly, Novo Nordisk to benefit as Pfizer's weight loss drug implodes
Eli Lilly (NYSE: LLY) and Novo Nordisk NYSE: NVO) stock prices have been some of the hottest names in Wall Street. NVO has soared by over 48% this year while LLY has surged by over 61%.
Maker of Wegovy, Ozempic showers money on U.S. obesity doctors
Drugmaker Novo Nordisk paid U.S. medical professionals at least $25.8 million over a decade in fees and expenses related to its weight-loss drugs, a Reuters analysis found.
Worried About a Weight-Loss Stock Bubble? Here Are Some Alternatives.
Eli Lilly and Novo Nordisk, riding the wave of enthusiasm for obesity meds, are seeing their stock prices soar. But behind them are coming new therapies from companies for investors that are drawn to ...